International Journal for Multidisciplinary Research (IJFMR)
E-ISSN: 2582-2160 ● Website: www.ijfmr.com ● Email: editor@ijfmr.com

The Role of Microbiome-Immune Crosstalk in Personalized Immunotherapy.

Antariksha Banik

Head of Operations, Medilab (India)

Abstract

The role of microbiome-immune crosstalk in personalized immunotherapy is an emerging area of research that explores how the intricate interactions between the human microbiome and the immune system can influence the effectiveness of cancer treatments, particularly immunotherapies. The human microbiome, a complex ecosystem of trillions of microorganisms, significantly affects various physiological processes, including immune function and inflammation, which are crucial in the context of cancer therapies such as immune checkpoint inhibitors (ICIs). Notably, research has revealed that specific gut microbial compositions can enhance or hinder the efficacy of these therapies, making the microbiome a potential biomarker for predicting treatment responses and guiding personalized therapeutic strategies.

This field is notable for its potential to transform cancer treatment paradigms by integrating microbiome profiling into clinical decision-making. Studies have shown that patients with a more diverse microbiome or certain beneficial microbial species tend to respond better to immunotherapy, highlighting the microbiome's role as a mediator of immune responses against tumors. Furthermore, the production of microbial metabolites, such as short-chain fatty acids, has been linked to enhanced immune activation and improved outcomes in cancer patients, underscoring the functional importance of microbiome-immune interactions.

However, the interplay between the microbiome and the immune system in cancer therapy is not without controversy. Dysbiosis, or an imbalance in the microbiome, has been associated with adverse effects of immunotherapy, including immune-related adverse events, complicating the therapeutic landscape. Moreover, the ethical implications of manipulating the microbiome for therapeutic purposes, as well as the challenges in standardizing microbiome-based interventions, raise important considerations for future clinical applications. As research continues to evolve, understanding the complexities of microbiome-immune crosstalk will be essential for optimizing personalized immunotherapy approaches and improving patient out- comes in oncology.

Keywords: Microbiome-immune crosstalk, Personalized immunotherapy, Cancer treatment, Immune checkpoint inhibitors (ICIs), Gut microbiome

The Microbiome

The human microbiome is a complex and dynamic ecosystem composed of trillions of microorganisms, including bacteria, fungi, viruses, and archaea, that inhabit various body sites, predominantly the gastrointestinal (GI) tract. In adults, the microbiota consists of around a dozen phyla, with Firmicutes and Bacteroidetes being the most predominant, followed by Actinobacteria, Proteobacteria, and Fusobacteria

[1]. The composition of these microbial communities varies significantly between individuals and is influenced by numerous factors, such as genetics, diet, environmental expo- sure, and the mode of delivery at birth [2].

Diversity and Composition

The diversity of the microbiome is considerably greater than the genomic variation found among individuals, with significant differences observed in the microbial composition of the gut and other body sites [2]. A healthy individual may harbor between 300 to 500 different bacterial species in their GI microbiome, yet the specific composition at the strain level is often unique to each individual, similar to a "fingerprint" [3]. This diversity plays a critical role in the host's immune response, digestion, and protection against pathogens [4].

Functional Importance

The functional components of the gut microbiome extend beyond mere presence, as individual microbial species can exhibit a wide array of metabolic capabilities and interactions with the host immune system [5]. For example, some gut bacteria produce short-chain fatty acids (SCFAs) that can influence immune responses and have been linked to conditions such as inflammatory bowel disease (IBD) and obesity [1]. Dysbiosis, or an imbalance in microbial communities, can lead to a variety of health issues, including autoimmune diseases, infections, and potentially impact the efficacy of cancer therapies, particularly immunotherapy[6].

Therapeutic Modulation

Recent research emphasizes the potential of modulating the microbiome for therapeutic benefits, particularly in enhancing the efficacy of immunotherapy [5]. Strategies may include the administration of probiotics or the selective depletion of harmful species using bacteriophages, which are viruses that specifically target bacteria [5]. Genetic manipulation of certain beneficial bacteria also offers a promising avenue for improving therapeutic outcomes by tailoring microbial functions to meet the needs of specific treatments [5].

Immune System Overview

The immune system plays a critical role in defending the body against pathogens and in modulating the response to tumors. It comprises various cell types and signaling pathways that work together to maintain homeostasis and respond to external threats. The system is broadly divided into innate and adaptive immunity, each with distinct mechanisms and functions.

Innate Immunity

Innate immunity is the body's first line of defense and is characterized by its rapid response to infections. It includes various cell types such as dendritic cells (DCs), macrophages, and innate lymphoid cells (ILCs), including natural killer (NK) cells. These cells recognize pathogens through pattern recognition receptors (PRRs) and respond by releasing cytokines and chemokines, which initiate inflammation and recruit other immune cells to the site of infection[7][8].

ILCs, particularly ILC3s, play a vital role in mucosal immunity, rapidly secreting cytokines that help combat pathogens and facilitate tissue repair[6]. Microbial signals from the gut microbiota are known to

shape the function and phenotypic diversity
of ILCs, illustrating the important interaction between the microbiome and innate immune responses[6].

Adaptive Immunity

Adaptive immunity involves a more specific response to pathogens and tumors, primarily mediated by T and B lymphocytes. CD4+ T cells (helper T cells) assist in orchestrating the immune response by secreting cytokines that activate other
immune cells, while CD8+ T cells (cytotoxic T cells) are responsible for directly killing infected or cancerous cells[9]. The differentiation of CD4+ T cells into various subsets, including regulatory T cells (Tregs) and Th17 cells, plays a crucial role in modulating immune responses and maintaining tolerance to self-antigens [9].

The interaction between the immune system and the gut microbiota has significant implications for immunotherapy. Studies have shown that specific gut microbes can enhance anti-tumor immune responses, particularly through the modulation of T cell responses. For example, certain Bacteroides species have been identified to promote Th1 differentiation, thereby improving the efficacy of immune checkpoint inhibitors (ICIs) [1]. Moreover, microbial metabolites like butyrate can influence intestinal barrier function and immune cell activation, further highlighting the impact of the microbiome on adaptive immunity [8] [10].

Immune System and Cancer

The relationship between the immune system and cancer is complex, with inflammation being a double-edged sword. Chronic inflammation can promote tumor development by creating a conducive environment for tumor initiation and progression [2].

Conversely, effective immune responses are crucial for controlling tumor growth and metastasis. Therapies that leverage the immune system, such as ICIs, have shown promise in treating various cancers, but they also carry risks of immune-related adverse effects, including colitis, which is believed to be influenced by microbiome dysbiosis [7].

Microbiome-Immune Crosstalk

The interplay between the gut microbiome and the immune system plays a crucial role in shaping immune responses, particularly in the context of cancer immunotherapy. The crosstalk between these two systems involves various mechanisms, including
the modulation of immune cell functions and the production of microbial metabolites that can influence systemic immunity.

Microbial Metabolites as Messengers

Microbial metabolites are important regulators of immune cell development and function. They can affect local and systemic antitumor immune responses, especially in the context of immune checkpoint inhibitor (ICI) therapy. These metabolites can be categorized into three groups: (1) those produced by the gut microbiota from dietary components, (2) host-derived metabolites modified by gut bacteria, and (3) metabolites synthesized de novo by the microbiota [5]. For instance, short-chain fatty acids (SCFAs) derived from the fermentation of dietary fibers have been shown
to enhance the memory potential of CD8+ T cells and improve intestinal barrier function [1].

Moreover, certain bacterial species, such as *Akkermansia muciniphila*, have been linked to improved efficacy of PD-1 blockade in cancer models, indicating that gut bacteria can augment adaptive immune responses through the induction of soluble immunomodulatory factors like IL-12 [5] [8].

Immune Cells as Messengers

The gut microbiota also influences the composition and functionality of immune cells, which act as messengers between the gut and systemic immune responses. Studies have demonstrated that specific gut microbes can enhance the functions of dendritic cells (DCs) and promote CD8+ T-cell priming and accumulation within the tumor microenvironment (TME) [8]. For instance, Bifidobacterium has been shown to augment the immune response by enhancing DC functions and facilitating T-cell activation, illustrating how microbial diversity can influence immune outcomes in cancer therapy [8].

Impact on Systemic Immunity

The systemic immune effects of the gut microbiome are multifaceted. Immune check- point inhibitors can alter gut microbiota composition, leading to changes in intestinal immune cells and metabolic pathways that affect overall immune responses [8].

Additionally, the gut microbiome can impact the activation thresholds of key immune subsets, thus modifying responses in the TME and tumor-draining lymph nodes (TdLN) [5]. For example, the presence of specific microbial populations has been correlated with improved ICI treatment outcomes in patients with certain cancers [8].

Role of Microbiome in Immunotherapy

The gut microbiome has emerged as a crucial player in the efficacy of immunotherapy for various cancers. Research indicates that specific microbial communities can influence the response to immune checkpoint blockade (ICB) therapies, which target T-cell receptors to enhance anti-tumor immunity [4] [7]. The microbiome's role can be

categorized into several predictive characteristics, including community structures, taxonomic compositions, and functional factors [3] [5].

Community Structures

Community structures of the gut microbiome, characterized by microbial diversity and composition, have been shown to correlate with treatment responses. Patients with a more diverse microbiome tend to exhibit better outcomes from immunotherapy, suggesting that the overall microbial landscape may significantly impact immune responses against tumors [5] [2].

Taxonomic Compositions

Certain specific microorganisms have been identified as potential biomarkers for predicting the efficacy of immunotherapy. For instance, *Akkermansia muciniphila* has shown promise as a common biomarker among responders in various cancers, including liver and lung cancer [3]. Additionally, in liver cancer patients, the presence of Lachnospiraceae bacterium and Alistipes sp. Marseille was linked to improved progression-free survival (PFS) and overall survival (OS) rates, whereas non-responders exhibited an abundance of Veillonellaceae, associated with worse clinical outcomes [3].

Functional Factors

Functional characteristics of the microbiome, such as metabolic pathways and the production of metabolites, can also serve as direct biomarkers for immunotherapy responses. These functional factors are closely related to immune system modulation and may help in understanding the mechanisms through which the microbiome influences therapy efficacy [3].

Therapeutic Interventions

Manipulating the gut microbiome through various therapeutic interventions may enhance immunotherapy outcomes. Strategies range from broad approaches to more targeted manipulations, aimed at optimizing the microbiome composition for better patient responses to treatments like anti-PD1 and anti-CTLA4 therapies [5] [2]. Such interventions not only have the potential to improve therapeutic efficacy but also to mitigate adverse effects associated with immunotherapy [9] [7].

Clinical Implications

Informed Consent and Ethical Considerations

In studies investigating the role of the microbiome in cancer immunotherapy, it is essential to obtain written informed consent from patients or their guardians for the publication of clinical details and images [11]. Ethical oversight is also critical, as
demonstrated by the approval from relevant Institutional Review Boards (IRB) and adherence to the World Medical Association Declaration of Helsinki [4].

Patient Population and Study Design

Research has primarily focused on patients with histopathologically confirmed lung cancer (LC) aged 18 years or older, who are undergoing treatment regimens that include immunotherapy, either as a monotherapy or in combination with chemotherapy [4]. This prospective cohort study, conducted at the University of Iowa Holden Comprehensive Cancer Center, highlights the importance of careful patient selection and monitoring throughout the treatment process. Limitations such as a small sample size and challenges in patient follow-up are noted, underscoring the need for larger studies to validate findings [11] [4].

Treatment Outcomes and Microbiome Dynamics

Preliminary results from clinical trials indicate that certain gut microbial taxa may be associated with positive treatment outcomes, including enhanced activation of CD8+ T cells and significant changes in the tumor microenvironment (TME) [6]. For instance, the presence of microbes such as has been correlated with improved clinical responses [6]. Moreover, trials involving fecal microbiota transplantation (FMT) have shown promise in overcoming resistance to immune checkpoint blockade (ICB), further suggesting the therapeutic potential of modulating the microbiome in cancer treatment [6].

Biomarkers and Predictive Models

The identification of gut microbiome signatures that predict the efficacy of immunotherapy is a key objective of ongoing studies such as the MITRE trial, which aims to enroll 1,800 participants across multiple cancer types [3]. This research may lead to the development of multimodal predictive models that incorporate a variety of biomarkers—including genomic and immune factors—to enhance the precision of immunotherapy strategies [3]. As shown in other studies, a combination of predictive factors such as CD8+ T-cell abundance and tumor mutational burden (TMB) may be required to better understand treatment efficacy and guide therapeutic decisions [3].

Future Directions and Collaborative Efforts

The integration of microbiome research into clinical oncology necessitates a collaborative approach among researchers, clinicians, and patients [4]. Initiatives that involve large-scale data collection and analysis can foster a deeper understanding of the microbiome's role in cancer immunotherapy and contribute to the personalized treatment landscape. This could lead to improved survival outcomes and quality of life for cancer patients as therapies evolve based on individual microbiome profiles and immune responses [2] [12].

Future Directions

Mechanistic Exploration and Therapeutic Strategies

Future research in the interplay between the microbiome and cancer immunotherapy will focus on mechanistic exploration to provide novel insights for developing microbiota-based therapeutic strategies. This includes manipulating gut microbiota through interventions such as fecal microbiota transplantation (FMT), probiotics, engineered microbiomes, and specific microbial metabolites to enhance the efficacy of immune checkpoint inhibitors (ICI) and optimize microbiota precision medicine [1]. The integration of diverse research methodologies, including microbiology, genetics, immunology, metabolomics, molecular pathology, and epidemiology, is anticipated to play a crucial role in the personalization of cancer therapy moving forward [1].

Probiotic and Prebiotic Innovations

The development of advanced probiotic technologies, such as the CRISPR Cas9 system and probiotic surface coating technology, presents promising avenues for therapeutic gains. These approaches aim to minimize disruption to the commensal microbiota while enhancing the effectiveness of cancer treatments [13]. Furthermore, research will continue to evaluate the effects of various probiotic and prebiotic formulations on immune responses and cancer immunotherapy outcomes, as inconsistencies in clinical evidence highlight the necessity for more extensive studies [8]. For instance, combining probiotics with prebiotics—known as synbiotics—has shown potential in enhancing anticancer immunity and improving treatment efficacy [9].

Understanding Microbiome Dynamics

A major challenge that remains is defining what constitutes a "healthy" microbiome in the context of cancer. The highly context-dependent nature of the gut microbiome complicates our understanding of its role in tumor dynamics and patient responses to therapy[2]. Future studies must address inter-individual variations and the impact of concurrent therapies on microbiome profiles to better understand their implications for immunotherapy [2]. Additionally, leveraging computational tools to analyze host-microbe interactions will be critical for developing targeted therapeutic interventions that can effectively modulate the microbiome to support cancer treatment [9].

Clinical Trials and Research Community Engagement

Emerging clinical trials will focus on integrating prebiotics, probiotics, and postbiotics with conventional cancer therapies. Research Topics led by prominent researchers will foster collaboration and innovation in this multidisciplinary field, potentially evolving into new specialty sections as community interest grows [14]. Engaging the scientific community in the development of these Research Topics will be essential to advance our understanding of microbiome-immune crosstalk in cancer immunotherapy, ultimately steering the future of personalized medicine [14] [4].

Funding Sources
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Ethical Approval and Informed Consent Statements:
This article does not contain any studies with human participants performed by the author.

Competing Interests:
The author declares no competing interests.

Data availability:
Data sharing is not applicable to this research, as no data were generated or analyzed.

References

1 . Lu, Y., Yuan, X., Wang, M., He, Z., Li, H., Wang, J., & Li, Q. (2022). Gut microbiota influence immunotherapy responses: Mechanisms and therapeutic strategies. Journal of Hematology & Oncology, 15(1), Article 47. https://doi.org/10.1186/s13045-022-01273-9

2. Jain, T., Sharma, P., Are, A. C., Vickers, S. M., & Dudeja, V. (2021). New insights into the cancer–microbiome–immune axis: Decrypting a decade of discoveries. Frontiers in Immunology, 12, Article 622064. https://doi.org/10.3389/fimmu.2021.622064

3 . Zhang, M., Liu, J., & Xia, Q. (2023). Role of gut microbiome in cancer immunotherapy: From predictive biomarker to therapeutic target. Experimental Hematology & Oncology, 12, Article 84. https://doi.org/10.1186/s40164-023-00442-x

4. Thompson, N. A., Stewart, G. D., Welsh, S. J., Doherty, G. J., Robinson, M. J., Neville, B. A., Vervier, K., Harris, S. R., Adams, D. J., Dalchau, K., Bruce, D., Demiris, N., Lawley, T. D., & Corrie, P. G. (2022). The MITRE trial protocol: A study to evaluate the microbiome as a biomarker of efficacy and toxicity in cancer patients receiving immune checkpoint inhibitor therapy. BMC Cancer, 22, Article 99. https://doi.org/10.1186/s12885-021-09156-x

5. Fessler, J., Matson, V., & Gajewski, T. F. (2019). Exploring the emerging role of the microbiome in cancer immunotherapy. Journal for ImmunoTherapy of Cancer, 7, Article 108. https://doi.org/10.1186/s40425-019-0574-4

6. Guo, C., Kong, L., Xiao, L., Liu, K., Cui, H., Xin, Q., Gu, X., Jiang, C., & Wu, J. (2023). The impact of the gut microbiome on tumor immunotherapy: From mechanism to application strategies. Cell & Bioscience, 13, Article 188. https://doi.org/10.1186/s13578-023-01135-y

7. Hayase, E., & Jenq, R. R. (2021). Role of the intestinal microbiome and microbial-derived metabolites in immune checkpoint blockade immunotherapy of cancer. Genome Medicine, 13, Article 107. https://doi.org/10.1186/s13073-021-00923-w

8. Li, Z., Xiong, W., Liang, Z., Wang, J., Zeng, Z., Kołat, D., Li, X., Zhou, D., Xu, X., & Zhao, L. (2024). Critical role of the gut microbiota in immune responses and cancer immunotherapy. Journal of Hematology & Oncology, 17, Article 41. https://doi.org/10.1186/s13045-024-01541-w

9. Singh, A., Alexander, S. G., & Martin, S. (2023). Gut microbiome homeostasis and the future of

probiotics in cancer immunotherapy. Frontiers in Immunology, 14, Article 1114499. https://doi.org/10.3389/fimmu.2023.1114499

10. Yoo, J. Y., Groer, M., Dutra, S. V. O., Sarkar, A., & McSkimming, D. I. (2020). Gut microbiota and immune system interactions. Microorganisms, 8(10), Article 1587. https://doi.org/10.3390/microorganisms8101587
11. Chau, J., Yadav, M., Liu, B., Furqan, M., Dai, Q., Shahi, S., Gupta, A., Mercer, K. N., Eastman, E., Abu Hejleh, T., Chan, C., Weiner, G. J., Cherwin, C., Lee, S. T. M., Zhong, C., Mangalam, A., & Zhang, J. (2021). Prospective correlation between the patient microbiome with response to and development of immune-mediated adverse effects to immunotherapy in lung cancer. BMC Cancer, 21, Article 808. https://doi.org/10.1186/s12885-021-08530-z
12. National Cancer Institute. (2018, February 5). Gut bacteria influence effectiveness of a type of immunotherapy. Cancer Currents Blog. https://www.cancer.gov/news-events/cancer-currents-blog/2018/gut-bacteria-checkpoint-inhibitors
13. Liu, C., Fu, L., Wang, Y., & Yang, W. (2024). Influence of the gut microbiota on immune cell interactions and cancer treatment. Journal of Translational Medicine, 22, Article 939. https://doi.org/10.1186/s12967-024-05709-3
14. Chauhan, N. S., Raghav, S. K., & Gupta, S. (Eds.). (2025). Host-microbiota immuno-interactions for personalized microbial therapeutics. Frontiers Media SA. https://doi.org/10.3389/978-2-88974-123-4